Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAY1225 PK in Renal Impairment
NCT06613763Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of RAY1225 in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Raynovent Biotech. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to T and Maximum Concentration. Started Sep 2024; status: completed.
02
Drugs
RAY1225
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06613763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613763.